Watch LRMR. Know when insiders buy.
One email the day a filing lands. Free.
LRMR
Larimar Therapeutics, Inc.
3.79
−0.01 −0.26%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
45
WATCH · shorts 45
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $393.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$172.6MNET CASH $78.1M52W 2.81 – 5.95SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$34.4M | −$32.8M | — | — | −$44M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | — | — | — | −$31.1M | −$29.6M | — | — | −$44.6M | — | — | Aug 4 |
| Q4 2025 · Dec 31derived | — | — | — | −$64M | −$62.5M | — | — | — | $0 | — | Mar 19 |
| Q3 2025 · Sep 30 | — | — | — | −$49.5M | −$47.7M | — | -0.61 | — | $23K | — | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$27.8M | −$26.2M | — | -0.41 | −$19.4M | $19K | −$19.4M | Aug 4 |
| Q1 2025 · Mar 31 | — | — | — | −$31.2M | −$29.3M | — | -0.46 | −$26.5M | $49K | −$26.6M | Aug 4 |
| Q4 2024 · Dec 31derived | — | — | — | −$31.3M | −$28.8M | — | -0.46 | −$21.8M | $179K | −$22M | Mar 19 |
| Q3 2024 · Sep 30 | — | — | — | −$18.3M | −$15.5M | — | -0.24 | −$24.5M | $62K | −$24.6M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$24.6M | −$21.6M | — | -0.34 | −$14M | — | — | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$16.7M | −$14.7M | — | -0.27 | −$10.4M | — | — | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$14.2M | −$13M | — | -0.29 | −$9.3M | — | — | Mar 24 |
| Q3 2023 · Sep 30 | — | — | — | −$10.3M | −$9.1M | — | -0.21 | −$9.2M | — | — | Oct 30 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$172.5M | −$165.7M | — | — | −$113.2M | $91K | −$113.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$90.9M | −$80.6M | — | -1.32 | −$70.8M | $515K | −$71.3M | — | — |
| FY2023 · to Dec 31 | — | — | −$41.8M | −$36.9M | — | -0.84 | −$33.5M | $164K | −$33.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$36.5M | −$35.4M | — | -1.37 | −$27.6M | $100K | −$27.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$50.5M | −$50.6M | — | -2.95 | −$42.1M | $333K | −$42.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$42.8M | −$42.5M | — | -3.57 | −$42.2M | $62K | −$42.3M | — | — |
Every number comes from Larimar Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.